Free tool
FAERS Monitor: Lomotil
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 012462 or its brand name (Lomotil, Atropine Sulfate, Diphenoxylate Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
13,731
Serious
9,029
66% of reports
Hospitalization
5,264
Death reported
1,344
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea2,763
- nausea1,634
- fatigue1,495
- drug ineffective1,136
- vomiting926
- weight decreased892
- pain786
- dehydration774
- off label use756
- abdominal pain749
- asthenia725
- headache683
- dyspnoea680
- decreased appetite654
- malaise597
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 219 |
| 2005 | 185 |
| 2006 | 220 |
| 2007 | 211 |
| 2008 | 250 |
| 2009 | 302 |
| 2010 | 333 |
| 2011 | 428 |
| 2012 | 616 |
| 2013 | 574 |
| 2014 | 669 |
| 2015 | 1,093 |
| 2016 | 1,027 |
| 2017 | 1,083 |
| 2018 | 1,119 |
| 2019 | 920 |
| 2020 | 913 |
| 2021 | 722 |
| 2022 | 618 |
| 2023 | 595 |
| 2024 | 582 |
| 2025 | 681 |
| 2026 | 371 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,040,428 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| dehydrationSignal | 774 | 8.9 | 8.3 | 5,449 |
| diarrhoeaSignal | 2,763 | 6.6 | 6.4 | 13,426 |
| abdominal painSignal | 749 | 4.9 | 4.6 | 2,372 |
| weight decreasedSignal | 892 | 4.9 | 4.6 | 2,799 |
| decreased appetiteSignal | 654 | 4.3 | 4.0 | 1,681 |
| nauseaSignal | 1,634 | 3.2 | 3.0 | 2,510 |
| vomitingSignal | 926 | 3.0 | 2.8 | 1,276 |
| astheniaSignal | 725 | 3.0 | 2.8 | 952 |
| fatigueSignal | 1,495 | 2.9 | 2.8 | 1,989 |
| malaiseSignal | 597 | 2.1 | 1.9 | 343 |
| pain | 786 | 2.0 | 1.8 | 380 |
| dyspnoea | 680 | 1.8 | 1.7 | 267 |
| headache | 683 | 1.7 | 1.6 | 188 |
| off label use | 756 | 1.3 | 1.2 | 62 |
| drug ineffective | 1,136 | 1.3 | 1.2 | 94 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.